Weili Duan, an accomplished inventor based in North Reading, MA, is at the forefront of innovation in the field of biochemistry. With her significant contributions to the development of engineered antibody fragments, she has made a notable impact in both diagnostics and therapeutics.

Latest Patents

Weili Duan holds a patent for "Engineered Monomeric Antibody Fragments." This invention involves monomeric polypeptides that incorporate an engineered monomeric antibody fragment, particularly monomeric Fc-containing polypeptides. These fragments feature engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. The patent details various methods for producing these engineered antibody fragments and outlines their applications in clinical diagnostics and therapeutic solutions.

Career Highlights

Duan currently works with Pfizer Corporation, a leading global biopharmaceutical company known for its groundbreaking medical innovations. Her role at Pfizer requires a blend of scientific expertise and innovative thinking, contributing to the advancement of new therapeutic approaches.

Collaborations

Throughout her career, Weili Duan has collaborated with distinguished colleagues, including Tetsuya Ishino and Ronald William Kriz. These partnerships showcase her ability to work within a team of experts to bring innovative ideas to fruition in the complex domain of biopharmaceutical research.

Conclusion

Weili Duan exemplifies the spirit of innovation in the scientific community, with her work on engineered monomeric antibody fragments setting a new benchmark in the field. Her advancements promise to enhance diagnostic methods and therapeutic strategies, reflecting her commitment to improving health outcomes worldwide.

Profile summary based on public USPTO records.